Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice.
Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice.
复制标题
小鼠副磷氟糖病毒5（PIV5）的结核病疫苗的功效。
DOI：
10.1016/j.vaccine.2015.10.124
复制
发表时间：
2015-12-16
期刊：
影响因子：
5.5
通讯作者：
He B
中科院分区：
文献类型：
--
作者：
Chen Z;Gupta T;Xu P;Phan S;Pickar A;Yau W;Karls RK;Quinn FD;Sakamoto K;He B
结核分枝杆菌（Mycobacterium tuberculosis，TB）是结核病（tuberculosis，TB）的病原体，是人类重要的病原体。卡介苗（BCG）是牛分枝杆菌的减毒活变种，是目前唯一可用的结核病疫苗，尽管其对成人感染性肺部疾病的效力较低。因此，需要更有效的结核病疫苗。副流感病毒5型（PIV 5）是一种副粘病毒，具有几个特性，使其成为一种有吸引力的疫苗载体。它是安全的，廉价的生产，并已被证明是有效的流感，狂犬病和呼吸道合胞病毒疫苗的骨干。本工作中，表达M.结核抗原85 A（PIV 5 - 85 A）和85 B（PIV 5 - 85 B）已经产生，并在小鼠气溶胶感染模型中评价了它们的免疫原性和保护效力。在一项长期保护研究中，发现单次给药PIV 5 - 85 A在降低M方面最有效。当与未接种疫苗的动物相比时，BCG接种疫苗的动物在肺中具有类似数量的结核菌落形成单位（CFU），而BCG接种疫苗的动物与未接种疫苗的动物具有类似数量的CFU。BCG初免后进行PIV 5 - 85 A或PIV 5 - 85 B加强接种产生了更好的结果，与PBS相比，肺CFU降低了近3个对数单位。结果表明，基于PIV 5的M.结核病疫苗是进一步开发的有希望的候选物。
Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), is an important human pathogen. Bacillus Calmette–Guérin (BCG), a live, attenuated variant of Mycobacterium bovis, is currently the only available TB vaccine despite its low efficacy against the infectious pulmonary form of the disease in adults. Thus, a more-effective TB vaccine is needed. Parainfluenza virus 5 (PIV5), a paramyxovirus, has several characteristics that make it an attractive vaccine vector. It is safe, inexpensive to produce, and has been previously shown to be efficacious as the backbone of vaccines for influenza, rabies, and respiratory syncytial virus. In this work, recombinant PIV5 expressing M. tuberculosis antigens 85A (PIV5-85A) and 85B (PIV5-85B) have been generated and their immunogenicity and protective efficacy evaluated in a mouse aerosol infection model. In a long-term protection study, a single dose of PIV5-85A was found to be most effective in reducing M. tuberculosis colony forming units (CFU) in lungs when compared to unvaccinated, whereas the BCG vaccinated animals had similar numbers of CFUs to unvaccinated animals. BCG-prime followed by a PIV5-85A or PIV5-85B boost produced better outcomes highlighted by close to three-log units lower lung CFUs compared to PBS. The results indicate that PIV5-based M. tuberculosis vaccines are promising candidates for further development.
登录
查看更多内容
影响因子：
5.4
作者：
Li, Zhuo;Gabbard, Jon D.;He, Biao
通讯作者：
He, Biao
DOI：
10.1054/tube.2001.0308
发表时间：
2001-01-01
期刊：
Tuberculosis (Edinburgh)
影响因子：
--
作者：
Brennan, M. J.;Fruth, U.
通讯作者：
Fruth, U.
影响因子：
5.4
作者：
Arimilli, S;Alexander-Miller, MA;Parks, GD
通讯作者：
Parks, GD
影响因子：
3.7
作者：
Chen, Zhenhai;Xu, Pei;He, Biao
通讯作者：
He, Biao
影响因子：
5.4
作者：
He, B;Lamb, RA
通讯作者：
Lamb, RA